Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3037% below fair value
$1.60−0.06 (-3.61%)
Close on Nov 17, 2026Market cap $13.19MP/E –Yield –
Lipocine total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Lipocine's total debt was $1.48M at Mar 31, 2022. For fiscal 2021 it was $2.31M, down 58.7% from the year before. The highest annual figure on record is $10.26M in fiscal 2018.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.31M | -58.7% |
| FY2020 | Dec 31, 2020 | $5.59M | -21.8% |
| FY2019 | Dec 31, 2019 | $7.15M | -30.3% |
| FY2018 | Dec 31, 2018 | $10.26M | – |
| FY2017 | Dec 31, 2017 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2022 | Mar 31, 2022 | $1.48M | -69.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.31M | -58.7% |
| Q3 FY2021 | Sep 30, 2021 | $3.14M | -50.7% |
| Q2 FY2021 | Jun 30, 2021 | $3.96M | -37.5% |
| Q1 FY2021 | Mar 31, 2021 | $4.78M | -24.8% |
| Q4 FY2020 | Dec 31, 2020 | $5.59M | -21.8% |
| Q3 FY2020 | Sep 30, 2020 | $6.36M | -19.9% |
| Q2 FY2020 | Jun 30, 2020 | $6.33M | -27.3% |
| Q1 FY2020 | Mar 31, 2020 | $6.35M | -33.1% |
| Q4 FY2019 | Dec 31, 2019 | $7.15M | -30.3% |
| Q3 FY2019 | Sep 30, 2019 | $7.94M | -22.2% |
| Q2 FY2019 | Jun 30, 2019 | $8.72M | -13.9% |
| Q1 FY2019 | Mar 31, 2019 | $9.49M | -5.7% |
| Q4 FY2018 | Dec 31, 2018 | $10.26M | – |
| Q3 FY2018 | Sep 30, 2018 | $10.19M | – |
| Q2 FY2018 | Jun 30, 2018 | $10.13M | – |
| Q1 FY2018 | Mar 31, 2018 | $10.06M | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
See a number that looks wrong?